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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a progressive lethal disorder of large motor
neurons of the spinal cord and brain. In approximately 20% of the familial and 2% of sporadic cases
the disease is due to a defect in the gene encoding the cytosolic antioxidant enzyme Cu, Zn-
superoxide dismutase (SOD1). The underlying molecular defect is known only in a very small
portion of the remaining cases and therefore involvement of other genes is likely. As SOD1
receives copper, essential for its normal function, by the copper chaperone, CCS (Copper
Chaperone for SOD), we considered CCS as a potential candidate gene for ALS.
Results: We have characterized the genomic organization of CCS and determined exon-intron
boundaries. The 823 bp coding region of the CCS is organized in 8 exons. We have evaluated
involvement of the CCS in ALS by sequencing the entire coding region for mutations in 20 sporadic
ALS patients.
Conclusions: No causative mutations for the ALS have been detected in the CCS gene in 20
sporadic ALS patients analyzed, but an intragenic single nucleotide polymorphism has been
identified.
Background
Copper serves as a cofactor for a number of oxygen-
processing enzymes involved in diverse metabolic proc-
esses, but the metal is highly toxic as a free ion. Upon en-
tering the cell the copper is bound to a number of copper
chelating transporters (copper chaperones), which guide
the copper ion to different cellular locations while pro-
tecting the cellular environment from the toxic effect of
copper. Copper chaperones are highly specific for their
targets and they participate directly in the loading of the
metal into the recipient molecule. One of the copper
chaperones is CCS (Copper Chaperone for SOD), which
targets copper to Cu, Zn-superoxide dismutase (SOD1)
[1].
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Superoxide dismutases are the major antioxidant enzymes
involved in free radical scavenging. These enzymes exist in
three distinct forms, where two of them contain copper
(SOD1 and SOD3), and the third one contains manga-
nese (SOD2). SOD1 (Cu, Zn-superoxide dismutase) is lo-
cated in the cytoplasm and peroxisomes, and the metal is
inserted into the enzyme in the cytosol by means of the
chaperone CCS after the enzyme has been synthesized [1].
The CCS gene has been localized to 11q13 and three func-
tional domains have been described in the 274 amino
acid long protein product [2,3]. Domain I (1–85) is the
copper binding site with the consensus MTCXXC motif
that is conserved in several other copper binding proteins
including HAH1, ATP7A/ATP7B and SOD1. This domain
is important in scavenging Cu from the cells and accepting
the metal from the transporters. Domain II (86–234) has
sequence homology to the SOD1 domain, which is asso-
ciated with Cu and Zn binding. Domain III (235–274)
contains a CXC motif, which is a copper site essential for
CCS-SOD1 transmetalation reaction. CCS interacts with
SOD1 by two putative metal binding sites at the opposite
ends via domains I and III [4]. It has been shown that cop-
per chaperone CCS can interact both with the wild type
and the SOD1 mutant in amyotrophic lateral sclerosis
(ALS) [5].
ALS is a progressive fatal disorder, which results from the
degeneration of motor neurons in the brain and spinal
cord. ALS is one of the most common adult-onset neuro-
degenerative disorders, leading to death within 2–5 years
of clinical onset. Approximately 10% of ALS patients are
familial cases and approximately 15–20% of these famil-
ial cases is associated with mutations in the SOD1 gene
[6–8]. Recently, homozygous mutations have been de-
scribed in the alsin gene, located at 2q33, and a new locus
has been proposed in a 8-Mb region on chromosome
18q21 in different families with various forms of FALS [9–
12]. In sporadic cases of ALS de novo mutations in the
SOD1 gene has only occasionally been observed [13–15].
Apparent heterogeneous distribution of ALS patients with
SOD1 gene mutations among different populations sug-
gests that other genetic loci should be involved in the dis-
ease.
In brain CCS and SOD1 co-localize within the same cell
types [15] and SOD1 can not acquire its Cu in the absence
of the CCS [16]. Due to its biological function we have
considered CCS as a potential candidate gene for ALS.
Herein we report the exon/intron structure of the human
CCS and the mutational analysis of the entire coding re-
gion of the gene in 20 individuals affected with ALS.
Results and discussion
Genomic organization of CCS
The genomic sequence of the CCS was obtained from the
sequence information of unordered fragments of two BAC
clones RP11-527H7 (AC019220.3) and CMB9-75A11
(AP000481) which were identified through a BLAST
[www.ncbi.nlm.nih.gov:80/blast/]  search of the NCBI
High-Throughput Genomic Sequences (HTGS) Database
using the cDNA sequence of the CCS gene (accession no:
AF002210). Correct orientation of the sequence and the
final order of the gene elements, coding and non-coding
regions were assembled by alignment of the CCS cDNA
sequence with genomic sequences. Exon-intron bounda-
ries were established by the identification of the conserved
splice site consensus sequences (table 1) and the results
were verified by sequencing exon-intron boundaries using
genomic DNA and intron specific primers placed within
at least 25 bp away from the exons (table 2).
Table 1: Exon intron structure of the CCS gene
Exon Exon Size (bp) 3' Splice acceptor 5' Splice donor Intron 
size (kb)
Nucleotide position AA position
1 82 GCACGgtgagggtcgag 0.341 1 – 82 1 – 13 domain I
2 73 ccgcccttgcagTTGGA GGCAGgtaagaacaggg 5.402 83 – 135 14 – 37
3 138 ctttcttgccagGTGTC GTTGCgtgagtgaccac 0.205 136 – 273 38 – 83
4 178 aataccttgcagAGAAT AACAGgtgagttgtctg 0.852 274 – 451 84 – 143 domain II
5 61 tttctttcttagCTGTG ACCGGgtaagtgtctgt 4.786 452 – 512 144 – 163
6 77 atctcattccagCACCG TGAAGgtaaggtggaaa 0.072 513 – 589 164 – 189
7 102 ctcccctcaaagGTGTG GAGAGgtgagtggtgtc 0.109 590 – 691 190 – 224
8 318 attcttctgcagGTTGG 692 – 1009 225 – 274 domain IIIBMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/5
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The 823 bp translated region of the CCS gene was organ-
ized in 8 exons and from the translation start site to the
translation termination site it spans 12798 bp of genomic
DNA (table 1). ATG translation start codon was in the 43
bp exon 1. The smallest exon was the 61 bp exon 5, while
the largest exon was the last exon (exon 8) which con-
tained the 150 bp translated sequence, TGA translation
termination site, 163 bp 3'-untranslated sequence and a
polyadenylation site. The splice donor and acceptor sites
in all exons conformed to the AG/GT rule [18,19]. The siz-
es of the introns were determined from the published se-
quences of the two BAC clones (Table 1). The smallest
intron was the 72-bp intron 6 and the largest was intron
2, which was 5402 bp long. All introns were type 0 (unin-
terrupted codon).
Database analysis  [http://www.friutfly.org/cgi-bin/
seq_tools/promoter.pl]  predicted two transcription start
sites at -300 to -250 bp and -1606 to -1565 bp within
1713 bp of genomic sequence upstream to the translation
initiation codon. In order to roughly determine the extent
of the 5' untranslated region of the CCS gene, a series of
RT-PCRs have been performed using 7 different forward
primers residing within a sequence of 1670 bp upstream
to the ATG start codon (starting at nucleotide positions -
1672, -1442, -871, -603, -302, -214 and -38, respectively)
-38, respectively) and the same reverse primer (5'-CGT-
GCAGAGGGTCCC-3', starting from nucleotide position
+22 of the CCS gene) downstream to the start codon. In
these reactions cDNA synthesized from human heart was
used and genomic DNA served as control. These analyses
suggested a transcription start site between nucleotides
588 and 302 upstream to the start codon. In the mean-
while, the results also suggested presence of another gene
in the opposite direction.
600 bp region upstream to the translation start site of CCS
gene was analyzed for presence of transcription factor
binding sites using Genomatics Genomatics MatInspector
Professional program  [http://www.genomatics.de] . Sites
for activator protein, zinc finger interaction domain, E-
box binding factor, X-box binding factor, myeloid zinc
finger 1 factor, myeloblast determining factor and winged
helix protein binding site have been detected within 430
bp in the 5' region of the gene with 100% core similarity
and 95% matrix similarity.
Mutation analysis of CCS in ALS patients
The entire protein-coding region of CCS was screened for
mutations in 20 ALS patients. In exon 8 a silent mutation
(847G>A) was detected in five Danish patients, where one
patient was homozygous and four were heterozygous.
Further screening of 25 Danish individuals revealed this
SNP in 9 chromosomes. The 847G>A transition was also
predicted as a candidate SNP by statistical analysis of hu-
man expressed sequence tags [20] and reported in the NC-
BI, Single Nucleotide Polymorphism database (ID 58140,
[http://www.ncbi.nlm.nih.gov/SNP/] ). The frequency of
this polymorphism in the Danish population analyzed in
the present study was calculated as 0.19 (15/80 independ-
ent chromosomes). Statistical analysis by Fishers test
showed no significant difference between this value and
the previously predicted frequency (LeeLab SNP database,
[http://www.bioinformatics.ucla.edu/snp/] ). In the NCBI
SNP Database there were two other predicted SNPs within
exon 8 of CCS (ID 55000 and 57614), those SNPs were
not detected among the 90 chromosomes analyzed in the
present study.
Conclusions
Sporadic patients comprise the majority of ALS cases (90
%) and the underlying genetic component is known in
only a small number of sporadic cases. Codon deletions
or insertion in the KSP repeat motif of the neurofilament
NF-H gene has been identified in ~1% of the sporadic ALS
cases [21]. Segregation of DNA markers flanking the CCS
Table 2: Primers and PCR conditions used for analysis of CCS gene
Exon Forward Reverse Product Size (bp) Annealing Temp (°C)*
1 CGCCGCGCTGGTTGGTG CGGCGAGGCTCCACACGAAG 138 57
2 CGATCATCGGTTGGT TAATAGATTCGCCTGGTC 173 51
3 CAGCCTCTGTTGCCCTCT ACCTTCCTCAAAGCCACTCC 285 57
4 CAAGCCAGCCCAAGTGTCTA TGAGGGCCCAGTGTGAAA 271 57
5 CCTGTGAGCTGCTTTCCT TCTGAGACTTTGGGTCCTCT 159 57
6 ATAGCAGCTTGGCACCAC GATGATGGACCCTGTTAGGA 184 57
7 TGGGCACCCTTCCTAACAG ACCATCCGCAGAGCACAG 201 57
8 CACCCCTGACCACACATT ATAAGGGGCATGGAGACAA 379 57
*PCR conditions: initial denaturation at 94°C for 5 min; 40 cycles of denaturation at 94°C (30 s), annealing (30 s), extention at 72°C (40 s); final 
extension at 72°C for 7 min.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/5
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gene was previously investigated in two FALS families but
no evidence of linkage was shown in these two families
[22]. Very recently the role of CCS in FALS has been stud-
ied by ablating the CCS gene in FALS-linked SOD1-mu-
tant mice. Although the absence of CCS led to a significant
reduction in the amount of copper loaded mutant-SOD1,
it did not modify the onset and progression of the disease
in FALS-linked SOD1-mutant mice [23]. In the present
study, we could not detect any disease causing mutations
in CCS among 20 sporadic ALS patients we have analyzed.
The genomic organization of the CCS gene and the intra-
genic SNP described in this study can be used in investi-
gating further ALS patients/families.
Materials and methods
20 sporadic cases of ALS (5 Greek and 15 Danish patients)
were investigated. The patient cohort was composed of 8
females and 12 males aged from 46 to 84. All the cases
met the criteria for ALS with both upper and lower motor
neuron involvement. The patients did not have any muta-
tions in the SOD1 gene.
Exons of the CCS gene were PCR amplified using intron
specific primers and 20 ng genomic DNA (table 2). PCR
was performed in a 15 µl reaction mixture containing 2.5
mM each dNTP, 12 pmol each primer, 0.1 U Taq DNA
polymerase (Amersham Life Science Inc.), 1 ×  reaction
buffer in a thermal cycler (MJ Research). For PCR condi-
tions see table 2. Amplification products were gel purified
and sequencing was performed on both strands with the
same amplification primers using Thermo Sequenase Ra-
diolabelled Terminator Cycle Sequencing kit (Amersham
Life Science Inc.) in a thermal cycler (MJ research).
The single nucleotide polymorphism (SNP) in exon 8
(847G>A), which destroyed a Fnu4HI recognition site was
screened in 25 healthy unrelated Danes using a PCR in-
duced restriction site assay. Following PCR amplification
of exon 8 (table 2), the 384 bp-PCR product was digested
with Fnu4H (New England Biolabs) producing 302 bp
and 82 bp fragments in the 847G allele, and 165 bp, 137
bp and 82 bp fragments in the 847A allele. The fragments
separated on a 2% agarose gel were visualized by ethid-
ium bromide staining.
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